RxDoctor Payments Data

Benigno Varela

Gastroenterology · Hamden, CTNPI 1730488412

Payments from drug & device makers

$16,026in general payments, 2019–2025

Across 297 payments — averaging $53.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ardelyx, Inc.$11K
  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$607
  • QOL Medical, LLC$389
  • Bristol Myers Squibb$344
  • Gilead$247
  • plus $2K from 20 others

What the payments were for

  • Speaking & faculty fees$7,50047%
  • Food & beverage$8,52653%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,026 in reported general payments places this provider in the 80th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$73,474
Medicare patients
193
Services billed
1,121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide107$127,966
XifaxanRifaximin34$110,719
IbsrelaTenapanor Hcl29$76,486
MotegrityPrucalopride Succinate76$73,180
Dexlansoprazole DrDexlansoprazole131$36,700
MovantikNaloxegol Oxalate20$14,218
Lubiprostone29$7,886
Mesalamine12$5,566
Budesonide EcBudesonide14$5,515
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates73$3,929
Pantoprazole Sodium283$2,895
Lactulose24$805
Esomeprazole Magnesium20$761
Omeprazole57$717
Famotidine23$624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,303$127,966107 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$196$110,71934 claims
Ardelyx, Inc.Ibsrela$10,612$76,48629 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$607$73,18076 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Hamden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →